Merit Medical Systems MMSI has been analyzed by 11 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 5 | 1 | 0 | 0 |
| Last 30D | 1 | 2 | 0 | 0 | 0 |
| 1M Ago | 2 | 1 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 2 | 2 | 1 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $93.45, along with a high estimate of $112.00 and a low estimate of $85.00. This upward trend is apparent, with the current average reflecting a 1.03% increase from the previous average price target of $92.50.
Understanding Analyst Ratings: A Comprehensive Breakdown
The analysis of recent analyst actions sheds light on the perception of Merit Medical Systems by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Michael Petusky | Barrington Research | Raises | Outperform | $100.00 | $98.00 |
| Jason Bednar | Piper Sandler | Raises | Overweight | $97.00 | $95.00 |
| Mike Matson | Needham | Lowers | Buy | $85.00 | $88.00 |
| Michael Petusky | Barrington Research | Maintains | Outperform | $98.00 | $98.00 |
| Kristen Stewart | CL King | Announces | Buy | $88.00 | - |
| Mike Matson | Needham | Maintains | Buy | $88.00 | - |
| Steven Lichtman | Oppenheimer | Raises | Outperform | $87.00 | $82.00 |
| Michael Petusky | Barrington Research | Raises | Outperform | $98.00 | $96.00 |
| Mike Matson | Needham | Raises | Buy | $88.00 | $81.00 |
| Jon Young | Canaccord Genuity | Raises | Buy | $112.00 | $102.00 |
| Craig Bijou | B of A Securities | Announces | Neutral | $87.00 | - |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Merit Medical Systems. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Merit Medical Systems compared to the broader market.
- Price Targets: Understanding forecasts, analysts offer estimates for Merit Medical Systems's future value. Examining the current and prior targets provides insight into analysts' changing expectations.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Merit Medical Systems's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Merit Medical Systems analyst ratings.
Discovering Merit Medical Systems: A Closer Look
Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for use in interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment. The United States generates the majority of the revenue.
Merit Medical Systems: Financial Performance Dissected
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Merit Medical Systems displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately 10.6%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Merit Medical Systems's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 8.51%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Merit Medical Systems's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 2.27%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Merit Medical Systems's ROA excels beyond industry benchmarks, reaching 1.34%. This signifies efficient management of assets and strong financial health.
Debt Management: Merit Medical Systems's debt-to-equity ratio is below the industry average at 0.74, reflecting a lower dependency on debt financing and a more conservative financial approach.
The Core of Analyst Ratings: What Every Investor Should Know
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
